This study by Miersch et al. uses modular design principles to combine neutralizing antibodies against two independent epitopes of the SARS-COV-2 spike protein into a single bi-paratopic, tetravalent antibody.
The tetravalent antibody behaves like conventional IgGs on yield, purity, stability, and solubility but demonstrates potency and breadth of coverage that far exceed conventional bivalent IgGs.
This tetravalent antibody platform offers enormous potential not just in infectious disease but also in oncology and other therapeutic areas.
The proprietary tetravalent antibody platform enables the efficient creation of antibodies in a high-throughput manner. Aarvik utilizes this platform to rapidly design and generate tetravalent antibodies against a variety of oncology targets.
These antibodies can elegantly combine multiple independent antibody paratopes to potentially improve the clinical activity of various therapeutic modalities, including antibody drug conjugates, which currently use conventional IgG antibodies.
Aarvik Therapeutics combines a unique, proprietary modular platform with multiple target mechanisms and therapeutic modalities to develop novel molecules with an improved therapeutic index for oncology and other diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer